3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment

      review-article
      , MD, PhD 1 , , MD, PhD 2 , , MD, PhD 3 , , MD, PhD 4 , , MD, PhD 5 , , MD, PhD 1 , , MD, PhD 6 , , MD, PhD 7 , , , MD, PhD 4 , , MD, PhD 2 , , MD, PhD 8 , , MD, PhD 9 , , MD, PhD 10 , on behalf of Committee of Clinical Practice Guidelines, Korean Society of Heart Failure
      International Journal of Heart Failure
      Korean Society of Heart Failure
      Heart failure, Guideline, Treatment, Pharmacotherapy

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The Korean Society of Heart Failure (KSHF) guidelines aim to provide physicians with evidence-based recommendations for the management of patients with heart failure (HF). After the first introduction of the KSHF guidelines in 2016, newer therapies for HF with reduced ejection fraction, HF with mildly reduced ejection fraction, and HF with preserved ejection fraction have since emerged. The current version has been updated based on international guidelines and research data on Korean patients with HF. Herein, we present Part II of these guidelines, which comprises treatment strategies to improve the outcomes of patients with HF.

          Related collections

          Most cited references109

          • Record: found
          • Abstract: not found
          • Article: not found

          2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            2018 ESC/ESH Guidelines for the management of arterial hypertension

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

              In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 diabetes.
                Bookmark

                Author and article information

                Journal
                Int J Heart Fail
                Int J Heart Fail
                IJHF
                International Journal of Heart Failure
                Korean Society of Heart Failure
                2636-154X
                2636-1558
                April 2023
                10 April 2023
                : 5
                : 2
                : 66-81
                Affiliations
                [1 ]Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, Catholic Research Institute for Intractable Cardiovascular Disease, College of Medicine, The Catholic University of Korea, Seoul, Korea.
                [2 ]Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
                [3 ]Department of Cardiovascular Medicine, Chonnam National University Medical School, Gwangju, Korea.
                [4 ]Division of Cardiology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
                [5 ]Department of Cardiology, Nowon Eulji Medical Center, Eulji University, Seoul, Korea.
                [6 ]Division of Cardiology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
                [7 ]Division of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
                [8 ]Division of Cardiology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.
                [9 ]Division of Cardiology, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.
                [10 ]Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
                Author notes
                Correspondence to Hyun-Jai Cho, MD, PhD. Division of Cardiology, Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea. hyunjaicho@ 123456snu.ac.kr ; hyunjaicho@ 123456gmail.com

                *Jong-Chan Youn and Darae Kim contributed equally to this article as first authors.

                Author information
                https://orcid.org/0000-0003-0998-503X
                https://orcid.org/0000-0003-3284-0904
                https://orcid.org/0000-0002-9393-2821
                https://orcid.org/0000-0001-8480-9082
                https://orcid.org/0000-0001-6521-303X
                https://orcid.org/0000-0003-0224-5178
                https://orcid.org/0000-0003-4211-3081
                https://orcid.org/0000-0002-2779-4037
                https://orcid.org/0000-0002-6710-685X
                https://orcid.org/0000-0002-2441-2267
                https://orcid.org/0000-0002-9767-7098
                https://orcid.org/0000-0002-3395-4279
                https://orcid.org/0000-0001-9856-9227
                Article
                10.36628/ijhf.2023.0011
                10172080
                37180564
                10075438-5d8a-4e0c-bd36-e9b9f9ab3637
                Copyright © 2023. Korean Society of Heart Failure

                This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 03 February 2023
                : 17 March 2023
                : 27 March 2023
                Categories
                Review Article

                heart failure,guideline,treatment,pharmacotherapy
                heart failure, guideline, treatment, pharmacotherapy

                Comments

                Comment on this article